Overall, we observed 956 genes differentially expressed between the SMAD1(+) and SMAD2(+) glioma cell populations (Bonferroni-adjusted P < 0.05); 671 genes were upregulated in SMAD2+ cells, while 285 were upregulated in SMAD1(+) cells. This evidence concerns the gene SMAD2 and central nervous system cancer.